

**Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2023/2024 influenza season**

as of January 24, 2025

	A(H1N1)pdm09						A(H3N2)						B				
	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir
<b>Resistant (%)</b>	2 (0.4%)	6 (0.5%)	6 (0.5%)	0	0	294 (100%)	4 (0.5%)	0	0	0	0	333 (100%)	0	0	0	0	0
<b>Number of viruses tested</b>	521	1,104	1,104	290	290	294	790	328	328	328	328	333	334	194	194	194	194
<b>Number of viruses reported</b>	2,183						3,696						2,188				

Baloxavir was examined by focus reduction assay, rhPCR allelic discrimination and/or PA sequencing.

NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.

Amantadine was examined by M2 sequencing.